RT Journal Article
SR Electronic
T1 Progress in oncolytic viruses modified with nanomaterials for intravenous application
JF Cancer Biology & Medicine
JO Cancer Biology & Medicine
FD China Anti-Cancer Association
SP 830
OP 855
DO 10.20892/j.issn.2095-3941.2023.0275
VO 20
IS 11
A1 Chen, Liting
A1 Ma, Zhijun
A1 Xu, Chen
A1 Xie, Youbang
A1 Ouyang, Defang
A1 Song, Shuhui
A1 Zhao, Xiao
A1 Liu, Funan
YR 2023
UL http://www.cancerbiomed.org/content/20/11/830.abstract
AB In oncolytic virus (OV) therapy, a critical component of tumor immunotherapy, viruses selectively infect, replicate within, and eventually destroy tumor cells. Simultaneously, this therapy activates immune responses and mobilizes immune cells, thereby eliminating residual or distant cancer cells. However, because of OVs’ high immunogenicity and immune clearance during circulation, their clinical applications are currently limited to intratumoral injections, and their use is severely restricted. In recent years, numerous studies have used nanomaterials to modify OVs to decrease virulence and increase safety for intravenous injection. The most commonly used nanomaterials for modifying OVs are liposomes, polymers, and albumin, because of their biosafety, practicability, and effectiveness. The aim of this review is to summarize progress in the use of these nanomaterials in preclinical experiments to modify OVs and to discuss the challenges encountered from basic research to clinical application.